Supercharged t cells take on Hard-to-Treat cancers
NCT ID NCT07614048
First seen May 30, 2026 · Last updated Jun 23, 2026 · Updated 5 times
Summary
This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infused back after a short course of chemotherapy. The goal is to control the disease in patients who have run out of standard options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered T cells (TCR-T cells) targeting mutant KRAS
What this could lead to
If successful, this could offer a new treatment option for patients with advanced pancreatic or colorectal cancers that have not responded to standard therapies.
What could go wrong
This is an early-stage expanded access program, not a large controlled trial. The treatment may not shrink tumors or improve survival, and there are risks from chemotherapy and cell infusion, including severe immune reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.